Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 11—November 2020
Dispatch

Multidrug-Resistant Hypervirulent Group B Streptococcus in Neonatal Invasive Infections, France, 2007–2019

Céline Plainvert, Constantin Hays1, Gérald Touak, Caroline Joubrel-Guyot2, Nicolas Dmytruk, Amandine Frigo, Claire Poyart, and Asmaa TaziComments to Author 
Author affiliations: Assistance Publique–Hôpitaux de Paris Centre Université de Paris, Paris, France (C. Plainvert, C. Hays, C. Joubrel-Guyot, N. Dmytruk, A. Frigo, C. Poyart, A. Tazi); Institut Cochin, Paris (C. Plainvert, G. Touak, C. Poyart, A. Tazi); FHU Prema, Paris (C. Plainvert, C. Poyart, A. Tazi); Université de Paris, Paris (C. Hays, C. Joubrel-Guyot, C. Poyart, A. Tazi)

Main Article

Table 1

Clinical manifestations, serotypes, and CC17 prevalence of group B Streptococcus neonatal invasive infections, France, 2007–2019*

Clinical manifestation EOD, no. (%) LOD, no. (%) p value
Bacteremia 298 (75.6) 442 (50.9) <0.0001#
Ia 69 (23.2) 45 (10.2) <0.0001**
Ib 13 (4.4) 8 (1.8)
II 30 (10.1) 6 (1.4)
III 149 (50.0) 359 (81.2)
IV 6 (2.0) 6 (1.4)
V 26 (8.7) 18 (4.1)
Others† 3 (1.0) 0
CC17
 122 (40.9)
 334 (75.6)
 <0.0001#
Meningitis‡ 95 (24.1) 397 (45.7) <0.0001#
Ia 15 (15.8) 39 (9.8) 0.33**
Ib 2 (2.1) 12 (3.0)
II 0 7 (1.8)
III 74 (77.9) 329 (74.4)
IV 2(2.1) 2 (0.5)
V 2 (2.1) 8 (2.0)
CC17
 65 (68.4)
 285 (71.8)
 0.52#
Others§ 1 (0.3) 29 (3.3) <0.0001#
III 0 24 (82.8)
Others¶ 1 5 (17.2)
CC17
 0
 21 (72.4)
Total 394 (100) 868 (100)

*CC, clonal complex; EOD, early-onset disease; LOD, late-onset disease.
†Including serotypes VI (2 isolates) and VIII (1 isolate).
‡GBS recovered from cerebrospinal fluid (470 cases) or GBS bacteremia associated with a cellular reaction in the cerebrospinal fluid (>20 leukocytes/mm3) and consistent clinical findings (4 EOD and 18 LOD cases).
§Including bone and joint and skin and soft tissue infections.
¶Including serotypes Ia (3 isolates), Ib (2 isolates), and V (1 isolate).
#χ2 test for the distribution of the clinical manifestations in EOD and LOD.
**χ2 test for serotype distribution or CC17 proportion in EOD and LOD during either bacteremia or meningitis.

Main Article

1Current affiliation: APHP-Nord (St. Louis) Université de Paris, Paris, France.

2Current affiliation: Le Raincy Hospital, Montfermeil, France.

Page created: August 13, 2020
Page updated: October 19, 2020
Page reviewed: October 19, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external